ANIK
Anika Therapeutics, Inc. NASDAQ Listed May 3, 1993$14.42
+1.34%
vs $14.23
Mkt Cap $206.8M
52w Low $8.10
80.0% of range
52w High $16.00
50d MA $14.83
200d MA $11.58
P/E (TTM)
-19.0x
EV/EBITDA
—
P/B
1.4x
Debt/Equity
0.2x
ROE
-7.6%
P/FCF
47.4x
RSI (14)
47.80
ATR (14)
$0.48
Beta
0.28
50d MA
$14.83
200d MA
$11.58
Avg Volume
71.9K
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
32 Wiggins Avenue · Bedford, MA 01730 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | -0.07 | 0.27 | +485.7% | 12.39 | +2.4% | +0.5% | +19.3% | -2.0% | +2.7% | +1.1% | — |
| Feb 26, 2026 | TNS | -0.12 | 0.31 | +348.0% | 12.79 | -0.9% | +12.3% | -0.3% | +0.6% | -0.3% | -0.8% | — |
| Nov 5, 2025 | TNS | 0.02 | 0.04 | +100.0% | 9.85 | +0.2% | -1.0% | +1.0% | +2.2% | +0.6% | -0.3% | — |
| Jul 30, 2025 | TNS | -0.13 | -0.13 | +0.0% | 8.10 | +0.0% | +2.0% | +4.6% | +1.5% | -4.8% | -1.2% | — |
| May 9, 2025 | TNS | 0.09 | -0.06 | -166.7% | 11.64 | +5.0% | +1.8% | +4.7% | -8.8% | +8.1% | -0.4% | — |
| Mar 12, 2025 | TNS | -0.01 | -0.03 | -200.0% | 17.11 | -4.1% | -11.1% | +4.6% | +1.3% | -1.6% | +0.6% | — |
| Oct 31, 2024 | TNS | 0.30 | -0.25 | -183.3% | 17.11 | +0.4% | -3.4% | +3.3% | -4.5% | +6.0% | -0.2% | — |
| Aug 8, 2024 | TNS | 0.23 | 0.17 | -26.1% | 25.68 | -1.9% | +0.0% | -2.4% | -0.2% | +1.1% | +1.0% | — |
| May 8, 2024 | TNS | -0.19 | -0.31 | -63.2% | 28.47 | -5.5% | -11.3% | +1.5% | -0.3% | +0.1% | +1.9% | — |
| Mar 13, 2024 | TNS | -0.26 | -4.30 | -1553.8% | 25.40 | -6.0% | -3.4% | +3.7% | -0.7% | +0.4% | +0.9% | — |
| Nov 2, 2023 | TNS | -0.33 | -0.45 | -36.4% | 18.99 | +27.5% | +11.2% | +0.4% | -1.0% | -1.2% | -1.7% | — |
| Aug 8, 2023 | TNS | -0.34 | -0.19 | +44.1% | 21.05 | +1.4% | -4.9% | -7.2% | -1.0% | +4.5% | -3.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27 | Barrington Research | Maintains | Outperform → Outperform | — | $12.79 | $12.67 | -0.9% | +12.3% | -0.3% | +0.6% | -0.3% | -0.8% |
| Jan 9 | Barrington Research | Maintains | Outperform → Outperform | — | $9.55 | $9.58 | +0.3% | -0.3% | -1.2% | +1.5% | -0.1% | -0.1% |
| Nov 6 | Barrington Research | Maintains | Outperform → Outperform | — | $9.85 | $9.87 | +0.2% | -1.0% | +1.0% | +2.2% | +0.6% | -0.3% |
| Sep 23 | Barrington Research | Maintains | Outperform → Outperform | — | $9.34 | $9.34 | +0.0% | -2.4% | -0.5% | -0.8% | +0.2% | +1.3% |
| Jul 31 | Barrington Research | Maintains | Outperform → Outperform | — | $8.10 | $8.10 | +0.0% | +2.0% | +4.6% | +1.5% | -4.8% | -1.2% |
| May 12 | Barrington Research | Maintains | Outperform → Outperform | — | $11.64 | $12.22 | +5.0% | +1.8% | +4.7% | -8.8% | +8.1% | -0.4% |
| Mar 13 | Barrington Research | Maintains | Outperform → Outperform | — | $17.11 | $16.41 | -4.1% | -11.1% | +4.6% | +1.3% | -1.6% | +0.6% |
| Nov 1 | Barrington Research | Maintains | Outperform → Outperform | — | $17.11 | $17.18 | +0.4% | -3.4% | +3.3% | -4.5% | +6.0% | -0.2% |
| Oct 22 | Barrington Research | Maintains | Outperform → Outperform | — | $24.44 | $24.48 | +0.2% | +1.1% | -0.6% | -0.1% | -0.8% | +1.4% |
| Aug 9 | Barrington Research | Maintains | Outperform → Outperform | — | $25.68 | $25.19 | -1.9% | +0.0% | -2.4% | -0.2% | +1.1% | +1.0% |
| May 29 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $24.76 | $24.96 | +0.8% | +3.6% | +0.3% | -0.2% | +4.0% | -1.1% |
| May 9 | Barrington Research | Maintains | Outperform → Outperform | — | $28.47 | $26.91 | -5.5% | -11.3% | +1.5% | -0.3% | +0.1% | +1.9% |
| Mar 14 | Barrington Research | Maintains | Outperform → Outperform | — | $25.40 | $23.87 | -6.0% | -3.4% | +3.7% | -0.7% | +0.4% | +0.9% |
| Mar 14 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $25.40 | $23.87 | -6.0% | -3.4% | +3.7% | -0.7% | +0.4% | +0.9% |
| Jan 3 | Barrington Research | Maintains | Outperform → Outperform | — | $22.66 | $22.59 | -0.3% | -0.1% | -1.9% | -0.6% | +2.5% | -0.8% |
| Nov 3 | Barrington Research | Maintains | Outperform → Outperform | — | $18.99 | $24.21 | +27.5% | +11.2% | +0.4% | -1.0% | -1.2% | -1.7% |
| Aug 14 | Barrington Research | Upgrade | Market Perform → Outperform | — | $18.38 | $19.40 | +5.5% | +4.5% | -3.7% | +0.0% | -0.1% | +1.8% |
| Aug 10 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $20.01 | $20.00 | -0.1% | -7.2% | -1.0% | +4.5% | -3.7% | +0.0% |
| May 31 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $27.06 | $26.97 | -0.3% | +0.1% | -1.4% | +2.1% | -2.0% | +0.8% |
| Mar 7 | Barrington Research | Downgrade | Outperform → Market Perform | — | $28.87 | $27.63 | -4.3% | -10.3% | +4.7% | -0.8% | -3.0% | -0.2% |
| Nov 9 | Barrington Research | Upgrade | Market Perform → Outperform | — | $27.37 | $28.21 | +3.1% | +8.1% | +7.8% | -2.6% | -0.8% | +1.4% |
| Mar 9 | Stephens & Co. | Downgrade | Overweight → Equal Weight | — | $30.60 | $28.75 | -6.0% | -14.3% | -5.8% | +3.6% | -0.5% | -0.4% |
| Dec 16 | Barrington Research | Upgrade | Market Perform → Outperform | — | $39.27 | $41.39 | +5.4% | +4.3% | +2.7% | +6.6% | -4.4% | +3.1% |
| Jan 21 | Sidoti & Co. | Upgrade | Neutral → Buy | — | $45.43 | $46.60 | +2.6% | +1.0% | -0.4% | +0.6% | -4.5% | +1.3% |
| Sep 23 | First Analysis | Downgrade | Strong Buy → Outperform | — | $53.12 | $51.86 | -2.4% | -0.4% | -0.3% | +0.7% | +0.6% | +0.9% |
| Feb 22 | Sidoti & Co. | Downgrade | Buy → Neutral | — | $40.49 | $37.27 | -8.0% | -16.2% | -1.7% | -2.5% | +2.0% | -1.7% |
| Jul 27 | Barrington Research | Upgrade | Market Perform → Outperform | — | $40.68 | $42.45 | +4.4% | -1.5% | -1.5% | +1.5% | +1.2% | +0.0% |
| Jun 20 | First Analysis | Downgrade | Overweight → Equal Weight | — | $46.12 | $33.32 | -27.8% | -37.6% | +3.3% | +4.2% | -1.0% | +2.6% |
| May 4 | Barrington Research | Upgrade | Market Perform → Outperform | — | $34.80 | $36.14 | +3.9% | +8.8% | +0.4% | -3.3% | -0.4% | +1.1% |
| Feb 23 | Barrington Research | Downgrade | Outperform → Market Perform | — | $57.71 | $49.02 | -15.1% | -10.4% | +3.1% | +1.7% | -4.0% | -1.0% |
| Jan 24 | First Analysis | Upgrade | Equal Weight → Overweight | — | $59.38 | $60.00 | +1.0% | +3.5% | +1.6% | +8.6% | +1.0% | -0.3% |
| Apr 27 | Northland Capital Markets | Downgrade | Outperform → Market Perform | — | $46.71 | $45.91 | -1.7% | -4.4% | +5.1% | -2.7% | -0.2% | -1.9% |
| Apr 27 | Northland Securities | Downgrade | Outperform → Market Perform | — | $46.71 | $45.91 | -1.7% | -4.4% | +5.1% | -2.7% | -0.2% | -1.9% |
| Feb 26 | Northland Securities | Maintains | Outperform → Outperform | — | $43.37 | $43.47 | +0.2% | +7.0% | -2.7% | -0.4% | -0.3% | +1.5% |
| Feb 26 | Northland Capital Markets | Maintains | Outperform → Outperform | — | $43.37 | $43.47 | +0.2% | +7.0% | -2.7% | -0.4% | -0.3% | +1.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | HENNEMAN JOHN B III | — | Buy | 5,000 | $14.66 | $73K | 54,871 | +2.75% | -1.56% |
| Apr 30, 2026 | Griffin Stephen D. | President and CEO | Buy | 12,200 | $12.29 | $150K | 36,163 | +19.28% | +0.13% |
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 1,544,460 | $15M | Added | Dec 2025 |
| 2 | Acadian Asset Management Llc | 606,544 | $9M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 605,777 | $9M | New | Mar 2026 |
| 4 | Renaissance Technologies Llc | 502,217 | $7M | Reduced | Mar 2026 |
| 5 | Capital Management Corp /va | 447,721 | $6M | Reduced | Mar 2026 |
| 6 | Aqr Capital Management Llc | 272,269 | $4M | Added | Mar 2026 |
| 7 | Two Sigma Investments, Lp | 236,120 | $3M | Added | Mar 2026 |
| 8 | D.e. Shaw & Co | 229,796 | $3M | Reduced | Mar 2026 |
| 9 | Ubs Group Ag | 133,074 | $2M | Added | Mar 2026 |
| 10 | Quantinno Capital Management Lp | 125,826 | $2M | Added | Mar 2026 |
| 11 | Man Group Plc | 124,293 | $2M | Added | Mar 2026 |
| 12 | Nuveen, Llc | 120,717 | $2M | Added | Mar 2026 |
| 13 | Northern Trust Corp | 111,836 | $2M | — | Mar 2026 |
| 14 | Jane Street Group, Llc | 134,768 | $1M | Added | Dec 2025 |
| 15 | Vanguard Portfolio Management Llc | 72,160 | $1M | New | Mar 2026 |
| 16 | Diker Management Llc | 53,662 | $778K | Reduced | Mar 2026 |
| 17 | Barclays Plc | 52,928 | $767K | Reduced | Mar 2026 |
| 18 | Citadel Advisors Llc | 52,062 | $755K | Added | Mar 2026 |
| 19 | R Squared Ltd | 50,184 | $728K | Added | Mar 2026 |
| 20 | Advyzon Investment Management, Llc | 49,855 | $723K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$206.8M
Enterprise Value
$173.5M
P/E (TTM)
-18.97x
Forward P/E
—
PEG Ratio
0.16x
P/B
1.44x
P/S
1.83x
P/FCF
47.40x
EV/EBITDA
—
Shares Out
14.3M
Financials (TTM)
Revenue
$112.8M
Net Income
-$10.9M
EBITDA
-$1.8M
Free Cash Flow
$4.4M
Op Cash Flow
$11.2M
EPS Basic
$-0.76
EPS Diluted
$-0.76
EPS Forward
$-0.20
Gross Margin
56.6%
Op Margin
-9.8%
Net Margin
-9.6%
Balance Sheet
Total Assets
$190.3M
Total Liab.
$46.8M
Total Equity
$143.5M
Cash
$57.5M
LT Debt
$24.2M
Book Value/Sh
$10.01
Debt/Equity
0.17x
Current Ratio
4.72
Quick Ratio
3.86
Returns & Growth
ROE
-7.6%
ROA
-5.7%
ROIC
-6.6%
Rev Growth YoY
-5.9%
EPS Growth YoY
+80.2%
Price Returns
2W
-5.3%
1M
+16.7%
3M
+1.2%
6M
+47.1%
12M
+30.3%
Technicals
52W High
$16.00
52W Low
$8.10
50d MA
$14.83
200d MA
$11.58
RSI (14)
47.80
ATR (14)
$0.48
Beta
0.28
Avg Volume
72K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 6:10pm
· Source: financialmodelingprep.com